SCHEMBL24320615

SCHEMBL24320615

CC(C)(C)OC(=O)N1CCN(c2cccc(OCc3ccc(Cl)cc3F)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 19/20 0.51
GPR119 Q8TDV5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30209272 1.00 GLP1R (0.51) GLP1RGPR119
SCHEMBL30798232 0.89 GLP1R (0.45) GLP1R
SCHEMBL25956295 0.88 GPR119 (0.49) GLP1RGPR119
SCHEMBL26913982 0.87 GLP1R (0.51) GLP1RGPR119
SCHEMBL24320504 0.87 GPR119 (0.49) GLP1RGPR119
SCHEMBL22391653 0.87 MKNK1 (0.43) GLP1R
SCHEMBL20266356 0.87 GLP1R (0.53) GLP1RGPR119
SCHEMBL29826099 0.87 GLP1R (0.53) GLP1RGPR119
SCHEMBL23362731 0.86 CKS1B (0.46) GLP1RGPR119
SCHEMBL24320732 0.86 GLP1R (0.54) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4650353-A1 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2025-11-19 EP disclosed
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-07-25 US disclosed
WO-2024149080-A1 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST 中国科学院上海药物研究所 2024-07-18 WO disclosed
CN-118344349-A 4-Alkoxybenzimidazole-6-carboxylic acid derivatives as GLP-1 receptor agonists 中国科学院上海药物研究所 2024-07-16 CN disclosed
CN-115461334-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-21 CN disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 US disclosed
EP-4242202-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-09-13 EP disclosed
CN-116547279-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 CN disclosed
CN-113831337-B GLP-1 receptor agonist, and pharmaceutical composition and use thereof 广州市恒诺康医药科技有限公司 2023-03-24 CN disclosed
CN-115461334-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-09 CN disclosed
WO-2022111624-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-06-02 WO disclosed
WO-2022111624-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-06-02 WO disclosed
WO-2022078407-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 WO disclosed
CN-113831337-A GLP-1 receptor agonist, and pharmaceutical composition and use thereof 广州市恒诺康医药科技有限公司 2021-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246959-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GLP1R, GIPR, GCGR GLP1R 1/4885GPR119 4/4885
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR GLP1R 1/4885GPR119 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.